ArticleChinese medicine2025
Notoginsenoside R1 mitigates UVB-induced skin sunburn injury through modulation of N
Article in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundIn recent years, skin sunburn injury caused by UVB has become a growing concern. Although PNS have demonstrated potential in alleviating this condition, the precise mechanisms involved remain incompletely elucidated. PURPOSE: This study was designed with three primary objectives. First, to apply network pharmacology-based predictive approaches to elucidate the mechanisms underlying PNS-mediated protection against UVB-induced skin sunburn injury. Second, to systematically analyze the chemical profile of PNS through UHPLC-Q-Orbitrap-MS/MS. Third, to conduct a comprehensive assessment of the pharmacodynamic properties of NGR1, a major bioactive constituent of PNS.
methodsThe chemical constituents of PNS were analyzed qualitatively and quantitatively using UHPLC and UHPLC-Q-Trap-MS/MS. Network pharmacology approaches were employed to identify the core molecular targets and potential mechanisms through which PNS alleviates UVB-induced sunburn injury. To evaluate the therapeutic effects of PNS and NGR1, an in vivo model was established using nude mice, while mechanistic studies were conducted in HaCaT cells to elucidate the underlying signaling pathways.
resultsA total of 16 primary saponins in PNS were successfully identified and quantified. Through network pharmacology analysis, 49 crucial molecular targets associated with PNS in the context of UVB-induced skin sunburn injury were revealed. Treatment with PNS and NGR1 ameliorated signs of photoaging via multiple mechanisms, including suppression of inflammatory responses, boosting antioxidant capacity, inhibition of the PI3K/AKT/mTOR signaling cascade, and regulation of proteins involved in maintaining cellular homeostasis. In HaCaT cells, PNS and NGR1 exert protective effects against apoptosis by modulating proteins associated with cellular homeostasis and autophagy. Both compounds counteracted the UVB-induced reduction in NAT10 expression. The degradation of NAT10, potentially mediated by the autophagy pathway involving key selective adaptors such as NBR1 and p62, may occur under both basal and UVB-exposed conditions.
conclusionPNS and NGR1 demonstrate promising therapeutic potential for the treatment of UVB-induced skin sunburn injury. Their capacity to mitigate photodamage via multiple mechanisms, such as inhibition of key signaling pathways, regulation of apoptosis and autophagy, and modulation of NAT10 expression, lays a strong foundation for future clinical studies on topical applications of PNS and NGR1, while also providing valuable insights into their preventive and curative effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.